Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Phase 2

Recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Liposomal Irinotecan
Drug: Carboplatin
Drug: 5-fluorouracil
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2018-12-05

Last Posted Date: 2024-07-31

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 320

Registration Number: NCT03764553

Locations: 🇳🇱
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
🇳🇱
Zuyderland Medisch Centrum, Geleen, Netherlands
🇳🇱
Tergooi ziekenhuizen, Hilversum, Netherlands

and more 32 locations

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

Phase 2

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Panitumumab
Drug: Irinotecan
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2018-11-23

Last Posted Date: 2021-06-30

Lead Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo

Target Recruit Count: 31

Registration Number: NCT03751176

Locations: 🇪🇸
ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain
🇪🇸
Hospital de Granollers, Granollers, Barcelona, Spain
🇪🇸
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain

and more 15 locations

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Phase 3

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Biological: Sintilimab
Drug: Cisplatin
Drug: Paclitaxel
Drug: Fluorouracil
Drug: Placebo

First Posted Date: 2018-11-20

Last Posted Date: 2023-10-24

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 746

Registration Number: NCT03748134

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇧🇪
Cliniques Universitaires Saint-Luc Av., Bruxelles, Hippocrate 10, Belgium

and more 44 locations

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Phase 2

Active, not recruiting

Conditions: Locally Advanced Digestive System Neuroendocrine Carcinoma
Locally Advanced Pancreatic Neuroendocrine Carcinoma
Refractory Pancreatic Neuroendocrine Carcinoma
Unresectable Digestive System Neuroendocrine Carcinoma
Metastatic Digestive System Neuroendocrine Carcinoma
Metastatic Pancreatic Neuroendocrine Carcinoma
Refractory Digestive System Neuroendocrine Carcinoma
Unresectable Pancreatic Neuroendocrine Carcinoma

Interventions: Drug: Fluorouracil
Drug: Leucovorin
Drug: Liposomal Irinotecan
Procedure: Quality-of-Life Assessment

First Posted Date: 2018-11-09

Last Posted Date: 2023-12-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 11

Registration Number: NCT03736720

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Stony Brook Cancer Center, Stony Brook, New York, United States

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Phase 2

Conditions: Advanced Esophageal Squamous Cell Cancer

Interventions: Drug: Irinotecan liposome
Drug: SHR-1316
Drug: Fluorouracil

First Posted Date: 2018-11-06

Last Posted Date: 2018-11-06

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT03732508

Locations: 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Irinotecan
Drug: Oxaliplatin
Drug: L-Leucovorin
Drug: 5-fluorouracil
Drug: Atezolizumab

First Posted Date: 2018-10-26

Last Posted Date: 2023-10-12

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 218

Registration Number: NCT03721653

Locations: 🇮🇹
Francesca Vannini, Pisa, Italia, Italy

Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Phase 1

Recruiting

Conditions: Colorectal Adenocarcinoma
Ewing Sarcoma

Interventions: Drug: INBRX-109
Drug: 5-fluorouracil
Drug: Carboplatin
Drug: Irinotecan
Drug: Temozolomide
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2018-10-23

Last Posted Date: 2024-12-12

Lead Sponsor: Inhibrx Biosciences, Inc

Target Recruit Count: 321

Registration Number: NCT03715933

Locations: 🇺🇸
Precision NextGen Oncology and Research, Beverly Hills, California, United States
🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸
Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States

and more 31 locations